Diabetic ketoacidosis remains a dangerous condition with a reported mortality of 6-10% in units having a special interest in its treatment [1] . It has long been known that low concentrations of red-cell 2,3-diphosphoglycerate (2,3-DPG) occur in this condition [2, 3, 4] . These low concentrations of 2,3-DPG 1 Present address: Dr. O.M. Gibby, Department of Clinical Biochemistry, New Addenbrookes Hospital, Cambridge tend to lessen the ability of the blood to release oxygen and so may cause tissue hypoxia. In diabetic ketoacidosis red cell 2,3-DPG concentrations may take up to five days to return to normal [4] . Hypophosphataemia also develops during the treatment of diabetic keoacidosis, and there is a close correlation between the rate of return to normal of plasma phosphate and of red-cell 2,3-DPG [7] . Consequently, many workers have suggested that phosphate administration should be part of the management of diabetic ketoacidosis, [4, 7, 8, 9] . The aim of this would be to hasten the recovery of red-cell 2,3-DPG and thus to improve oxygen availability from the blood. However, no information has been available as to the efficacy of phosphate in enhancing oxygen release in diabetic ketoacidosis. We have measured plasma phosphate, red-cell 2,3-DPG and the haemoglobin-oxygen affinity during the ten days following admission to hospital in 21 patients, 11 of whom received phosphate replacement in addition to a standard regime for diabetic ketoacidosis.
Patients, Materials and Methods
Consecutive patients were included in the study if they were in diabetic ketoacidosis, with an arterial blood pH of less than 7.35, a blood glucose concentration greater than 25 mmol/1 and ketonuria. Three patients, one of whom was studied on three occasions, are represented in both groups. Three other patients were retrospectively omitted from this report, two patients who died (a 79-year old woman with cardiac failure and mitral valve disease, and a 52-year old man after a massive myocardial infarct), and a third patient with acute renal failure. In all 3 patients it was felt that the complications would themselves interfere with oxygen handling and complicate the interpretation of the results.
All patients received a constant insulin (Actrapid M. C., Novo) infusion, starting at 6.6 iu/hour (not corrected for insulin adsorption to plastic syringe and tubing) via a Harvard pump. The infusion rate was gradually reduced to maintain a blood glucose of less than 10 mmol/1. Fluid and electrolyte replacement were given as 0012-186X/78/0015/0381/$01.00 Gall bladder disease Ischamic heart disease Thyrotoxicosis Down's syndrome clinically indicated, using saline (0.154 mol/l) and subsequently dextrose (5 g/100 ml) solutions. In control patients, Group 1 (Table 1) , potassium replacement was given as the chloride. The phosphate supplemented patients, Group 2 (Table 2) , were given IV molar potassium hydrogen phosphate (K2HPO4) in doses sufficient to replace potassium. The mean dose of phosphate was 118 mmol (range 83-320 mmol) over 2 days. The dose of IV phosphate was adjusted so as to restore and maintain normal plasma phosphate concentrations (normal range 0.8-1.45 mmol/1). When patients in Group 2 were able to eat, IV phosphate was replaced by 4-8 phosphate-Sandoz tablets (each containing 12 mmol phosphate) daily for 10 days and were transferred to a three times per day sliding scale of insulin based on blood glucose levels. After 24-48 h a twice daily regime of Actrapid and Monotard M. C. insulin was instituted. None of the patients was given sodium bicarbonate. Arterial blood samples were drawn anaerobically and assayed within 20 minutes for pH, oxygen tension and standard bicarbonate. Blood glucose was measured on a Beckman glucose analyser. Plasma calcium, phosphate [10] and albumin were measured by autoanalyser techniques. Red-cell 2,3-DPG was determined on blood deproteinized at the bedside, according to Sigma Technical Bulletin No. 35-UV (Sigma Labs., U. S.), which depends on the decrease in NADH concentrations measured at 340 nm, after the enzymic conversion of 2,3-DPG to 1,3-DPG and subsequent reduction.
The blood oxygen tension at 50% haemoglobin-oxygen saturation (p 50) was derived from the simultaneously measured haemoglobin-oxygen saturation and oxygen tension in fresh whole blood at saturations of 40-50%, 50% and 50-60% using the "1I, 217 blood gas laboratory" (Instrumentation Laboratory, U. K.). p 50 standard (pH = 7.4, pCO2 = 40 mm Hg) and p 50 in vivo (actual venous pH and base excess) were calculated from this, using the following expressions: log p 50 standard = log p 50 (measured) -0.40 (7.4 -pH of assay) log p 50 in vivo = log p 50 (measured) + 0.59 (assay pH -in vivo pH) + 0.003 A base excess These expressions were derived from observations on normal subjects and are similar to those quoted elsewhere [11] .
Since the differences between assay and in vivo pH values were slight (average difference 0.04 units), the correction factors from assay p 50 to p 50 in vivo were small. Alterations in the Bohr factor due to variations in 2,3-DPG concentrations [12] introduce only minimal variation in the predicted p 50 in vivo. We have therefore used a single pH and base excess correction factor rather There were no significant differences between the values of p 50 standard at any time.
In both groups there was a good correlation between the p 50 standard and the concentrations of 2,3-DPG (p < 0.001).
The regression equations are as follows: Group 1 : p 50 --19.2 + 0.35 (DPG) Group 2 : p 50 = 19.5 + 0.24 (DPG) Normal : p 50 = 17.6 + 0.69 (DPG) [14] .
p 50 in vivo
Initial values of p 50 in vivo were high but values in the two groups were not significantly different. In both groups lowest levels were reached between 12 h and 2 days. At 4 days only, p 50 values were lower in Group 2 (p < 0.05).
'Available Oxygen'
This calculation includes both oxygen content and p 50 in vivo. There was no significant difference between the two groups on admission or subsequently. Values fell at 24 h. Haemoglobin concentrations on admission were high due to dehydration. 'Available Oxygen' was therefore calculated using the patients' 
Discussion
This study has demonstrated in diabetic ketoacidosis that phosphate infusion adequate to prevent hypophosphataemia increases the rate of recovery of red-cell 2,3-DPG but only after the first twenty-four hours. However, no significant improvement in haemoglobin-oxygen affinity results at any time. The concentration of haemoglobin Ale, which was not measured in our study, is increased in poorly controlled diabetics [15] . The high affinity for oxygen of haemoglobin Alc is little affected by 2,3-DPG [16] . In phosphate treated patients this may have contributed to the failure of the p 50 to rise in parallel with their more rapid recovery of erythrocyte 2,3-DPG concentrations.
We find that p 50 in diabetic patients is less sensitive to changes in concentrations of 2,3-DPG than in normal subjects. This contrasts with the findings of Ditzel and Standl in their study of non-acidotic juvenile diabetics [17] . However, both findings are based on the results of population surveys where factors other than the concentration of 2,3-DPG e. g. pH, pCO2 and phosphate, are varying, and individually influencing p 50 in their separate ways. Ditzel and Standl's findings in their juvenile non-acidotic diabetic subjects cannot necessarily be extrapolated to patients with diabetic ketoacidosis.
The patients in our study varied considerably in age, duration of diabetes and presumably also in pulmonary, cardiac and renal function. As groups however, they were similar (Tables 1 and 2 ). There was no clinical difference in their response to treatment. Only modest reductions in calculated oxygen availability were found in our patients. At the time of maximal reduction in oxygen availability from the blood, these patients have improved considerably in their clinical state due to the correction of hyperglycaemia, acidosis and dehydration. No practical measurement of tissue oxygenation is available so that direct detection of the effects of changes in 'Available Oxygen' is not possible.
The role of bicarbonate therapy in diabetic ketoacidosis is controversial. Theoretically, it might reduce oxygen availability by rapid correction of acidosis. This induces an immediate 'left shift' of the oxygen dissociation curve before the restoration of red-cell 2,3-DPG. In this study 6 patients with an arterial pH of less than 7.0 on admission were treated successfully without bicarbonate.
We have demonstrated that phosphate can be administered safely provided the dose is carefully judged. Impairment of renal function, however, would be a contra-indication to phosphate treatment. Phosphate administration, by mouth or intravenously, causes metastatic soft tissue calcification and renal impairment in patients with hypercalcaemia [18, 19] . Patients presenting with diabetic ketoacidosis are dehydrated and have raised blood urea concentrations and it is difficult to exclude underlying or impending renal failure. Great care is essential in the administration of phosphate, and we did not see any deterioration in renal function in our patients over the study period. Phosphate administration causes hypocalcaemia. A rapid plasma phosphate estimation would be a valuable safeguard in its use.
Unless it can be demonstrated that actual tissue oxygenation is improved by phosphate treatment in diabetic ketoacidosis, the case for phosphate remains unproven and we conclude that phosphate administration, at least in the doses used in the present study, is not indicated to improve tissue oxygenation in diabetic ketoacidosis.
